Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

358

10.17650/1994-4098-2008-0-3-20-23

MAMMOLOGY. LECTURE

МАММОЛОГИЯ. ЛЕКЦИИ

Screening mammography in the diagnosis of cancer in situ

РОЛЬ И МЕСТО СКРИНИНГОВОЙ МАММОГРАФИИ В ДИАГНОСТИКЕ РАКА IN SITU

Komarova

L. Ye.

Комарова

Л. Е.

Russian Federation

ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва

16082008

20231709201417092014

2008

https://ojrs.abvpress.ru/ojrs/article/view/358

Screening mammography in the diagnosis of cancer in situ

РОЛЬ И МЕСТО СКРИНИНГОВОЙ МАММОГРАФИИ В ДИАГНОСТИКЕ РАКА IN SITU

1. Рак молочной железы. Под ред. М.И. Давыдова, В.П. Летягина. М.; 2006.

Рак молочной железы. Под ред. М.И. Давыдова, В.П. Летягина. М.; 2006.

2. Silva O.E., Zurrida S. Breast cancer: a practical guide. 3rd. NY, Elsevier; 2005. p. 54—5.

Silva O.E., Zurrida S. Breast cancer: a practical guide. 3rd. NY, Elsevier; 2005. p. 54—5.

3. Luke C., Priest K., Roder D. Changes in incidence of in situ and invasive breast cancer by histology type following mam- mography screening. Asian Pac J Cancer Prev 2006;7(1):69—74.

Luke C., Priest K., Roder D. Changes in incidence of in situ and invasive breast cancer by histology type following mam- mography screening. Asian Pac J Cancer Prev 2006;7(1):69—74.

4. Julien J.-P. et al on behalf of the EORTC Breast Cancer Cooperative Group and the EORTC Radiotherapy Group. Radiotherapy in breast-conserv- ing treatment for ductal carcinoma in situ: first results from the EORTC ran- domized phase III trial 10853. Lancet 2000;355:528—33.

Julien J.-P. et al on behalf of the EORTC Breast Cancer Cooperative Group and the EORTC Radiotherapy Group. Radiotherapy in breast-conserv- ing treatment for ductal carcinoma in situ: first results from the EORTC ran- domized phase III trial 10853. Lancet 2000;355:528—33.

5. Fisher B., Dignam J., Wolmar K.N. et al. Tamoxifen in treatment of intraduc- tal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993—2000.

Fisher B., Dignam J., Wolmar K.N. et al. Tamoxifen in treatment of intraduc- tal breast cancer. National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993—2000.

6. UK Coordinating Committee on Cancer Research (UK CCCR) Ductal Carcinoma in situ (DCIS). Working Party on behalf of DCIS trialists in the UK, Australia and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized con- trolled trial. Lancet 2003;362:95—102.

UK Coordinating Committee on Cancer Research (UK CCCR) Ductal Carcinoma in situ (DCIS). Working Party on behalf of DCIS trialists in the UK, Australia and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia and New Zealand: randomized con- trolled trial. Lancet 2003;362:95—102.

7. Fisher B., Land S., Mamonnas E. et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adju- vant breast and bowel project experience. Semin Oncol 2001;28(4):400—18.

Fisher B., Land S., Mamonnas E. et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adju- vant breast and bowel project experience. Semin Oncol 2001;28(4):400—18.

8. Evans A.J., Pinder S.E., Ellis I.O. et al. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or obligate precursor of invasive disease? J Med Screen 2001;8:149—51.

Evans A.J., Pinder S.E., Ellis I.O. et al. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or obligate precursor of invasive disease? J Med Screen 2001;8:149—51.

9. Claus E.B., Stowe M., Carter D. Breast carcinoma in situ; risk factors and screening patterns. J Natl Cancer Inst 2001;93(23):1811—7.

Claus E.B., Stowe M., Carter D. Breast carcinoma in situ; risk factors and screening patterns. J Natl Cancer Inst 2001;93(23):1811—7.

10.

10. Summer W.E., Koniaris L.G., Snell S.E. et al. Results of 23810 cases of ductal carcinoma in situ. Ann Surg Oncol 2007;14:1540—50.

Summer W.E., Koniaris L.G., Snell S.E. et al. Results of 23810 cases of ductal carcinoma in situ. Ann Surg Oncol 2007;14:1540—50.

11.

11. Irvine T., Fentiman I.S. Biology and treatment of ductal carcinoma in situ. Expert Rev Anticancer Ther 2007;7(2):135—45.

Irvine T., Fentiman I.S. Biology and treatment of ductal carcinoma in situ. Expert Rev Anticancer Ther 2007;7(2):135—45.

12.

12. Ernster V.L., Ballard-Barbash R., Barlow W.E. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2003;95(6):487—8.

Ernster V.L., Ballard-Barbash R., Barlow W.E. et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2003;95(6):487—8.

13.

13. Kaplan R.M., Saltzstein S.L. Reduced mammographic screening may explain declines in breast carcinoma in older women. J Am Geriatr Soc 2005;53(5):862—6.

Kaplan R.M., Saltzstein S.L. Reduced mammographic screening may explain declines in breast carcinoma in older women. J Am Geriatr Soc 2005;53(5):862—6.

14.

14. Erbas B., Amos A., Fletcher A. et al. Incidence of invasive breast cancer carci- noma in situ in a screening program by age : should older women continue screening? Cancer Epidemiol Biomarkers Prev 2004;13(10):1569—73.

Erbas B., Amos A., Fletcher A. et al. Incidence of invasive breast cancer carci- noma in situ in a screening program by age : should older women continue screening? Cancer Epidemiol Biomarkers Prev 2004;13(10):1569—73.

15.

15. Li J., Hemminki K. Risk for con- tralateral breast cancers in population covered by mammography: effects of family history, age at diagnosis and histol- ogy. Breast Cancer Res Treat 2007; 105(2):229—36.

Li J., Hemminki K. Risk for con- tralateral breast cancers in population covered by mammography: effects of family history, age at diagnosis and histol- ogy. Breast Cancer Res Treat 2007; 105(2):229—36.

16.

16. Claus E.B., Stowe M. et al. The risk of contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 2003;12(6):451—6.

Claus E.B., Stowe M. et al. The risk of contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 2003;12(6):451—6.

17.

17. Daly M.B. Tamoxifen in ductal car- cinoma in situ. Semin Oncol 2006;33(6):647—9.

Daly M.B. Tamoxifen in ductal car- cinoma in situ. Semin Oncol 2006;33(6):647—9.

18.

18. Evans A.J., Pinder S., Ellis I.O. et al. Screening-detected and sympto- matic ductal carcinoma in situ: mammo- graphic features with pathologic correla- tion. Radiology 1994;191(1):

Evans A.J., Pinder S., Ellis I.O. et al. Screening-detected and sympto- matic ductal carcinoma in situ: mammo- graphic features with pathologic correla- tion. Radiology 1994;191(1):

19.

237—40.

—40.

20.

19. Shin H.J., Kim H.H., Kim S.M. et al. Screening-detected and sympto- matic ductal carcinoma in situ: differ- ences in the sonographic and pathologic features. Am J Roentgenol 2008;190(2):516—25.

Shin H.J., Kim H.H., Kim S.M. et al. Screening-detected and sympto- matic ductal carcinoma in situ: differ- ences in the sonographic and pathologic features. Am J Roentgenol 2008;190(2):516—25.

21.

20. Li C.I., Malone K.E., Satzman B.S. et al. Risk of invasive breast carcinoma among women diagnosed with ductal car- cinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006;106(10):2104—12.

Li C.I., Malone K.E., Satzman B.S. et al. Risk of invasive breast carcinoma among women diagnosed with ductal car- cinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006;106(10):2104—12.

22.

21. Hwang E.S., Mc Lennan J.L., Moore D.H. et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25(6):642—7.

Hwang E.S., Mc Lennan J.L., Moore D.H. et al. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 2007;25(6):642—7.

23.

22. Claus E.B., Petruzella S., Carter D. et al. Prevalence of BRCA 1 and BRCA 2 mutations in women diagnosed with duc- tal carcinoma in situ. JAMA 2005;294(5):553—4.

Claus E.B., Petruzella S., Carter D. et al. Prevalence of BRCA 1 and BRCA 2 mutations in women diagnosed with duc- tal carcinoma in situ. JAMA 2005;294(5):553—4.

24.

23. Smith K.L., Adank M., Kauff N. et al. BRCA mutation in women with ductal carcinoma in situ. Clin Cancer Res 2007;13(14):4306—10.

Smith K.L., Adank M., Kauff N. et al. BRCA mutation in women with ductal carcinoma in situ. Clin Cancer Res 2007;13(14):4306—10.